Gaudy-Marqueste C.
- Country
- France
- Department
- Dermatologie et Vénérologie
Research Overview
- Phase II Study of Sequential Encorafenib and Binimetinib Followed by Nivolumab and Ipilimumab Versus Immediate Nivolumab and Ipilimumab in BRAF V600 Mutant Melanoma
- Phase 1/2 Open-Label Study of PRS-344/S095012 and Obinutuzumab in Patients with Solid Tumors
- Phase 2 Multicenter Study of Patritumab Deruxtecan in Patients with Locally Advanced or Metastatic Solid Tumors
Data & Insights
Has run more than one trial at 49 of 117 partner sites.
Specializations
Oncologic Therapeutics
The investigator pursues innovative treatments across a spectrum of solid malignancies, emphasizing targeted and immunomodulatory strategies.
- melanoma
- soft tissue sarcoma
- pancreatic neuroendocrine tumors
- uterine leiomyosarcoma
- head and neck squamous cell carcinoma
Research integrates molecular profiling to refine patient selection for novel agents.
Neuroimmunology
Focus is placed on immune‑mediated central nervous system disorders, exploring disease‑modifying agents.
- multiple sclerosis
- fingolimod
- interferon‑β‑1a
- immune modulation
- long‑term safety
Efforts aim to balance efficacy with tolerability in chronic neuroinflammatory disease.
Cardiovascular & Pulmonary Vascular Medicine
Investigations address acute and chronic vascular pathologies, targeting reperfusion and hemodynamic control.
- acute ischemic stroke
- pulmonary hypertension
- acute myocarditis
- P2Y12 inhibition
- mechanical thrombectomy
Therapeutic goals include reducing tissue injury and improving functional recovery.
Pediatric Neurological & Oncologic Disorders
Dedicated to rare pediatric conditions, the work emphasizes safety and activity of emerging compounds.
- KCNT1‑related developmental and epileptic encephalopathy
- pediatric cancer
- Wilms tumor
- metronomic chemotherapy
- dose optimization
Studies prioritize age‑appropriate dosing while preserving therapeutic benefit.
Dermatology & Venereology Oncology
Within the dermatologic domain, the investigator concentrates on cutaneous malignancies and related immunotherapies.
- cutaneous melanoma
- immune checkpoint inhibition
- adjuvant therapy
- skin‑associated viral oncogenesis
- clinical outcome measures
Efforts seek to translate systemic advances into dermatologic practice.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.